Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? S Gill, CL Loprinzi, DJ Sargent, SD Thomé, SR Alberts, DG Haller, ... Journal of clinical oncology 22 (10), 1797-1806, 2004 | 1323 | 2004 |
A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients DJ Sargent, RM Goldberg, SD Jacobson, JS Macdonald, R Labianca, ... New England Journal of Medicine 345 (15), 1091-1097, 2001 | 1168 | 2001 |
Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials DJ Sargent, HS Wieand, DG Haller, R Gray, JK Benedetti, M Buyse, ... Journal of Clinical Oncology 23 (34), 8664-8670, 2005 | 781 | 2005 |
Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials D Sargent, A Sobrero, A Grothey, MJ O'Connell, M Buyse, T Andre, ... Journal of Clinical Oncology 27 (6), 872, 2009 | 724 | 2009 |
Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia … PF Conte, J Latreille, L Mauriac, F Calabresi, R Santos, D Campos, ... Journal of Clinical Oncology 14 (9), 2552-2559, 1996 | 327 | 1996 |
Folinic acid and 5-fluorouracil as adjuvant chemotherapy in colon cancer G Francini, R Petrioli, L Lorenzini, S Mancini, S Armenio, G Tanzini, ... Gastroenterology 106 (4), 899-906, 1994 | 321 | 1994 |
End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the … DJ Sargent, S Patiyil, G Yothers, DG Haller, R Gray, J Benedetti, M Buyse, ... J Clin Oncol 25 (29), 4569-4574, 2007 | 280 | 2007 |
Effects of salmon calcitonin in postmenopausal osteoporosis: a controlled double-blind clinical study GF Mazzuoli, M Passeri, C Gennari, S Minisola, R Antonelli, C Valtorta, ... Calcified tissue international 38, 3-8, 1986 | 255 | 1986 |
Regulatory (FoxP3+) T-cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo or chemoimmunotherapy P Correale, MS Rotundo, MT Del Vecchio, C Remondo, C Migali, ... Journal of immunotherapy 33 (4), 435-441, 2010 | 249 | 2010 |
Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin … P Correale, MG Cusi, KY Tsang, MT Del Vecchio, S Marsili, ML Placa, ... Journal of Clinical Oncology 23 (35), 8950-8958, 2005 | 201 | 2005 |
Ovarian ablation versus goserelin with or without tamoxifen in pre-perimenopausal patients with advanced breast cancer: results of a multicentric Italian study F Boccardo, A Rubagotti, A Perrotta, D Amoroso, M Balestrero, ... Annals of oncology 5 (4), 337-342, 1994 | 196 | 1994 |
Comparison between a cisplatin‐containing regimen and a carboplatin‐containing regimen for recurrent or metastatic bladder cancer patients: A randomized phase II study R Petrioli, B Frediani, A Manganelli, G Barbanti, B De Capua, ... Cancer: Interdisciplinary International Journal of the American Cancer …, 1996 | 193 | 1996 |
Adjuvant epirubicin with or without ifosfamide for adult soft-tissue sarcoma R Petrioli, A Coratti, P Correale, C D’Aniello, L Grimaldi, G Tanzini, ... American journal of clinical oncology 25 (5), 468-473, 2002 | 132 | 2002 |
Immunity feedback and clinical outcome in colon cancer patients undergoing chemoimmunotherapy with gemcitabine+ FOLFOX followed by subcutaneous granulocyte macrophage colony … P Correale, P Tagliaferri, A Fioravanti, MT Del Vecchio, C Remondo, ... Clinical Cancer Research 14 (13), 4192-4199, 2008 | 97 | 2008 |
Treatment of colon and breast carcinoma cells with 5‐fluorouracil enhances expression of carcinoembryonic antigen and susceptibility to HLA‐A (*) 02.01 restricted, CEA‐peptide … P Correale, A Aquino, A Giuliani, M Pellegrini, L Micheli, MG Cusi, ... International journal of cancer 104 (4), 437-445, 2003 | 97 | 2003 |
Dendritic cell-mediated cross-presentation of antigens derived from colon carcinoma cells exposed to a highly cytotoxic multidrug regimen with gemcitabine, oxaliplatin, 5 … P Correale, MG Cusi, MT Del Vecchio, A Aquino, S Prete, KY Tsang, ... The Journal of Immunology 175 (2), 820-828, 2005 | 94 | 2005 |
Exemestane after tamoxifen as adjuvant hormonal therapy in postmenopausal women with breast cancer: effects on body composition and lipids G Francini, R Petrioli, A Montagnani, A Cadirni, S Campagna, E Francini, ... British journal of cancer 95 (2), 153-158, 2006 | 88 | 2006 |
Disease-free survival (DFS) vs. overall survival (OS) as a primary endpoint for adjuvant colon cancer studies: individual patient data from 12,915 patients on 15 randomized trials DJ Sargent, S Wieand, J Benedetti, R Labianca, DG Haller, LE Shepherd, ... Journal of Clinical Oncology 22 (14_suppl), 3502-3502, 2004 | 88 | 2004 |
Changes in bone turnover and in bone mass in women with breast cancer switched from tamoxifen to exemestane S Gonnelli, A Cadirni, C Caffarelli, R Petrioli, A Montagnani, MB Franci, ... Bone 40 (1), 205-210, 2007 | 81 | 2007 |
Neurotoxicity of FOLFOX-4 as adjuvant treatment for patients with colon and gastric cancer: a randomized study of two different schedules of oxaliplatin R Petrioli, A Pascucci, E Francini, S Marsili, A Sciandivasci, R Tassi, ... Cancer chemotherapy and pharmacology 61, 105-111, 2008 | 79 | 2008 |